Although clinical outcomes remain controversial, the emerging therapeutic use of targeted inhibitors has made their detection essential in AML, as they might improve the prognosis of IDH1/2-mutated AML patients [8]. The gene discussed is IDH1; the disease is acute myeloid leukemia.